It was demonstrated that bezafibrate administration led to improvement in fatty acid oxidation disorders in TFP-deficient patient fibroblasts and reduction of myopathic manifestations in patients with TFP deficiency [78,79]. The gene discussed is TRIM39; the disease is hyperinsulinemic hypoglycemia, familial, 4.